Mark Slevin holds the position of Chair in clinical biomedicine at the ICCC-CSIC in St Pau Hospital, Barcelona, and the Chair in cell pathology in the School of Biology, Chemistry, and Health Science at Manchester Metropolitan University. From 2007 to 2010, he was also a Fellow of the Royal College of Pathologists in Spain. Slevin was recently awarded the title of Eminent Scientist of the Year in Cardio-Pathology by the International Research Promotions Council in 2011 for his work, which he completed during his sabbatical period. He is the Editor-in-Chief of the Vascular Cell Journal and the Editor of the Brain Pathology Journal amongst others. Slevin is a Fellow of the Institute of Biomedical Scientists in the UK. He is a recognised expert in the field of angiogenesis research and, in particular, in investigations of the role of angiogenesis in both stroke and cardiovascular diseases. He was the first to identify the potent antiangiogenic properties of opticin in association with proliferative diabetic retinopathy, signaling mechanism of hyaluronan, and the importance of monomeric C-reactive protein in brain pathology and stroke. Slevin works closely with senior postdoctoral research scientists Drs. Matou and Bosutti. The work of the group has been/is being supported by the Wellcome Trust, the Diabetes UK, the Royal Society, the Pathological Society of Great Britain and Northern Ireland, and internationally through the Mizutani Foundation for Glycoscience, the BBVA Bank of Spain, and the Plan Nacional of Spain. Slevin is a Member of the panel of expert reviewers of the Wellcome Trust, reviews for ERA-NET, the Medical Research Council, and the BBSRC. He is also a Fellow of numerous societies including the European Stroke Association and the American Heart/Stroke Association (FAHA).
Biography Updated on 1 August 2016